Revenue Breakdown
Composition ()
No data
Revenue Streams
AngioDynamics Inc (ANGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Med Device, accounting for 53.4% of total sales, equivalent to $40.45M. Another important revenue stream is Med Tech . Understanding this composition is critical for investors evaluating how ANGO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, AngioDynamics Inc maintains a gross margin of 53.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.17%, while the net margin is -7.99%. These profitability ratios, combined with a Return on Equity (ROE) of -15.26%, provide a clear picture of how effectively ANGO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ANGO competes directly with industry leaders such as KIDS and MLAB. With a market capitalization of $403.93M, it holds a significant position in the sector. When comparing efficiency, ANGO's gross margin of 53.05% stands against KIDS's 73.92% and MLAB's 61.46%. Such benchmarking helps identify whether AngioDynamics Inc is trading at a premium or discount relative to its financial performance.
